Royalty Pharma plc - Class A (NASDAQ:RPRX)

Stock Price: $33.42

+0.25 (0.75%)

Updated Jun 2, 2023 08:00 PM GMT+0000

Featured app

Invest now

77% of retail CFD accounts lose money.

Overview

Financials

Statistics

Profile

Chart

Market Cap	14.98B
Revenue	2.36B
Gross Profit	2.36B
Shares Out	448.20M
EPS (ttm)	0.7576
PE Ratio	45.1406
Forward PE	8.2394
Dividend Rate (ttm)	0.7702
Dividend Yield	0.0230

Trading Day	Jun 2
Last Price	$33.42
Previous Close	$33.17
Change ($)	0.25
Change (%)	0.75%
Day's Open	33.34
Day's Range	33.265 - 33.805
Day's Volume	2.83M
52 Week Range	32.02 - 43.7

About Royalty Pharma plc - Class A

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products.

royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies.

royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi.

News

Here’s what Warren Buffet was buying and selling in Q3 November 16, 2021

Top 3 undervalued US biotech stocks to buy before it is too late October 12, 2021

Quick info

Country

United States

Industry

Medicinal and Botanical Manufacturing

Sector

Manufacturing

Employees

CEO

Pablo Gerardo Legorreta

Address

110 East 59Th Street
New York
New York
10022

Phone

12128830200

Website

royaltypharma.com

Ticker Symbol

RPRX

Exchange

NASDAQ Stock Exchange

Reporting Currency

USD

Royalty Pharma plc - Class A income statements (2023) (USD)

	May 2023
Total Revenue	683.97M
Cost of Revenue	0
Gross Profit	683.97M
Research & Development	500K
Selling General & Admin	85.70M
Operating Expense	86.20M
Operating Income	597.78M
Other Income Expense Net	-118.8M
EBIT	513.58M
Interest Income	30.25M
Pretax Income	509.09M
Income Tax	0
Minority Interest	168.33M
Net Income	340.76M
Net Income Basic	340.76M

Royalty Pharma plc - Class A income statements (2022) (USD)

	August 2022	August 2022	May 2022	May 2022	February 2022
Total Revenue	535.96M	535.96M	562.05M	562.05M	2.29B
Cost of Revenue	0	0	0	0	0
Gross Profit	535.96M	535.96M	562.05M	562.05M	2.29B
Research & Development	606K	606K	100.50M	100.50M	200.08M
Selling General & Admin	51.84M	51.84M	51.54M	51.54M	182.83M
Operating Expense	52.45M	52.45M	157.71M	157.71M	878.24M
Operating Income	483.51M	483.51M	404.34M	404.34M	1.41B
Other Income Expense Net	-105.71M	-105.71M	-184.62M	-184.62M	0
EBIT	378.53M	378.53M	220.12M	220.12M	1.41B
Interest Income	36.05M	36.05M	37.53M	37.53M	112.61M
Pretax Income	491.60M	491.60M	128.08M	128.08M	1.24B
Income Tax	0	0	0	0	0
Minority Interest	187.09M	187.09M	76.32M	76.32M	621.47M
Net Income	304.50M	304.50M	51.76M	51.76M	619.73M
Net Income Basic	304.50M	304.50M	51.76M	51.76M	619.73M

Royalty Pharma plc - Class A income statements (2021) (USD)

	November 2021	August 2021	August 2021	May 2021	May 2021	February 2021
Total Revenue	585.77M	554.96M	554.96M	573.03M	573.03M	2.12B
Cost of Revenue	0	0	0	0	0	0
Gross Profit	585.77M	554.96M	554.96M	573.03M	573.03M	2.12B
Research & Development	90.50M	3.12M	3.12M	2.64M	2.64M	26.29M
Selling General & Admin	48.59M	44.92M	44.92M	43.16M	43.16M	181.72M
Operating Expense	144.88M	53.78M	53.78M	345.65M	345.65M	461.90M
Operating Income	440.89M	501.19M	501.19M	227.38M	227.38M	1.66B
Other Income Expense Net	-137.84M	243.76M	243.76M	0	0	0
EBIT	305.80M	762.65M	762.65M	227.38M	227.38M	1.70B
Interest Income	32.07M	23.39M	23.39M	20.82M	20.82M	128.68M
Pretax Income	221.80M	806.76M	806.76M	158.98M	158.98M	1.70B
Income Tax	0	0	0	0	0	0
Minority Interest	119.87M	365.98M	365.98M	89.86M	89.86M	726.91M
Net Income	101.93M	440.78M	440.78M	69.12M	69.12M	0.98B
Net Income Basic	101.93M	440.78M	440.78M	69.12M	69.12M	0.98B

Royalty Pharma plc - Class A balance sheet (2023) (USD)

	February 2023
Current Cash	1.74B
Receivables	36.60M
Inventory	0
Current Assets	2.55B
Other Current Assets	781.84M
Short Term Investments	781.84M
Long Term Investments	14.26B
Property/Plant Equipment	0
Good Will	N.A
Intangible Assets	0
Tangible Assets (Net)	5.63B
Other Assets	13.52B
Total Assets	16.81B
Accounts Payable	0
Other Current Liabilities	169.27M
Total Current Liabilities	1.17B
Total Liabilities	11.19B
Long Term Debt	6.12B
Current Long Term Debt	1B
Minority Interest	3.90B
Common Stock	442.29M
Treasury Stock	-2.81M
Retained Earnings	1.96B
Capital Surplus	N.A
Shareholder Equity	5.63B
Other Liabilities	N.A

Royalty Pharma plc - Class A balance sheet (2022) (USD)

	August 2022	May 2022
Current Cash	2.76B	2.34B
Receivables	35.35M	65.81M
Inventory	0	0
Current Assets	3.50B	2.98B
Other Current Assets	706.36M	576.07M
Short Term Investments	706.36M	576.07M
Long Term Investments	14.24B	14.40B
Property/Plant Equipment	0	0
Good Will	N.A	N.A
Intangible Assets	0	0
Tangible Assets (Net)	6.03B	5.78B
Other Assets	13.46B	13.47B
Total Assets	17.74B	17.38B
Accounts Payable	0	0
Other Current Liabilities	182.33M	135.87M
Total Current Liabilities	182.33M	135.87M
Total Liabilities	11.71B	11.60B
Long Term Debt	7.11B	7.10B
Current Long Term Debt	0	0
Minority Interest	4.38B	4.36B
Common Stock	436.32M	433.96M
Treasury Stock	-2.75M	-2.74M
Retained Earnings	2.45B	2.22B
Capital Surplus	N.A	N.A
Shareholder Equity	6.03B	5.78B
Other Liabilities	N.A	N.A

Royalty Pharma plc - Class A balance sheet (2021) (USD)

	November 2021	August 2021	May 2021
Current Cash	2.11B	2.05B	1.85B
Receivables	73.50M	44.84M	40M
Inventory	0	0	0
Current Assets	2.78B	2.71B	2.42B
Other Current Assets	588.69M	608.95M	529.05M
Short Term Investments	588.69M	608.95M	529.05M
Long Term Investments	14.96B	13.81B	13.50B
Property/Plant Equipment	0	0	0
Good Will	N.A	N.A	N.A
Intangible Assets	11.47M	17.26M	23M
Tangible Assets (Net)	5.78B	5.72B	4.86B
Other Assets	14.02B	12.94B	12.61B
Total Assets	17.73B	16.51B	15.91B
Accounts Payable	0	0	0
Other Current Liabilities	255.06M	283.99M	255.98M
Total Current Liabilities	255.06M	283.99M	255.98M
Total Liabilities	11.94B	10.78B	11.03B
Long Term Debt	7.09B	5.83B	5.82B
Current Long Term Debt	0	0	0
Minority Interest	4.59B	4.67B	4.95B
Common Stock	428.23M	409.34M	389.76M
Treasury Stock	-2.69M	-2.66M	-2.36M
Retained Earnings	2.32B	2.29B	1.92B
Capital Surplus	N.A	N.A	N.A
Shareholder Equity	5.79B	5.73B	4.88B
Other Liabilities	N.A	N.A	N.A

Royalty Pharma plc - Class A cash flow (2023) (USD)

	May 2023	February 2023
Net Income	340.76M	-456.08M
Depreciation	0	5.67M
Changes in Receivables	38.44M	36.60M
Changes in Inventories	0	0
Cash Change	1.98B	1.74B
Cash Flow	1.03B	569.93M
Capital Expenditures	-601.71M	-250.24M
Investments	N.A	N.A
Investing Activity (other)	N.A	N.A
Total Investing Cash Flows	-558.53M	414.74M
Dividends Paid	N.A	N.A
Net Borrowings	4.53B	4.60B
Other Financing Cash Flows	N.A	N.A
Cash Flow Financing	-210.37M	-265.55M
Exchange Rate Effect	N.A	N.A

Royalty Pharma plc - Class A cash flow (2022) (USD)

	November 2022	August 2022	May 2022	February 2022
Net Income	142.65M	304.50M	51.76M	4.07B
Depreciation	0	0	0	771M
Changes in Receivables	34.84M	35.35M	65.81M	28.08B
Changes in Inventories	0	0	0	0
Cash Change	1.54B	2.76B	2.34B	21.38B
Cash Flow	538.83M	574.95M	460.27M	3.22B
Capital Expenditures	-1.32B	-175.01M	-85K	-695M
Investments	N.A	N.A	N.A	N.A
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-1.43B	-30.18M	11.17M	716M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	4.80B	3.64B	4.18B	33.70B
Other Financing Cash Flows	N.A	N.A	N.A	N.A
Cash Flow Financing	-230.09M	-228.25M	-220.97M	-3.63B
Exchange Rate Effect	N.A	N.A	N.A	N.A

Royalty Pharma plc - Class A cash flow (2021) (USD)

	November 2021	August 2021	May 2021
Net Income	101.93M	440.78M	69.12M
Depreciation	-11.4M	5.73M	5.67M
Changes in Receivables	73.50M	44.84M	40M
Changes in Inventories	0	0	0
Cash Change	2.11B	2.05B	1.85B
Cash Flow	469.76M	531.72M	526.10M
Capital Expenditures	-2.02B	0	0
Investments	N.A	N.A	N.A
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-845.5M	126.17M	-599.3M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	4.39B	3.16B	3.45B
Other Financing Cash Flows	N.A	N.A	N.A
Cash Flow Financing	1.03B	-224.42M	-226.67M
Exchange Rate Effect	N.A	N.A	N.A

Royalty Pharma plc - Class A dividends (USD)

Ex date	Payment date	Record date	Declared date	Amount	Description	Frequency
18-05-2023	15-06-2023	19-05-2023	N.A	0.20	Ordinary Shares - Class A	Quarterly
15-02-2023	15-03-2023	16-02-2023	N.A	0.20	Ordinary Shares - Class A	Quarterly
17-11-2022	15-12-2022	18-11-2022	N.A	0.19	Ordinary Shares - Class A	Quarterly
18-08-2022	15-09-2022	19-08-2022	N.A	0.19	Ordinary Shares - Class A	Quarterly
17-02-2022	15-03-2022	18-02-2022	N.A	0.19	Ordinary Shares - Class A	Quarterly
19-08-2021	15-09-2021	20-08-2021	N.A	0.17	Ordinary Shares - Class A	Quarterly
19-05-2021	15-06-2021	20-05-2021	N.A	0.17	Ordinary Shares - Class A	Quarterly
18-02-2021	15-03-2021	19-02-2021	N.A	0.17	Ordinary Shares - Class A	Quarterly
19-11-2020	15-12-2020	20-11-2020	N.A	0.15	Ordinary Shares - Class A	Quarterly
14-09-2020	30-09-2020	15-09-2020	N.A	0.15	Ordinary Shares - Class A	Quarterly

Royalty Pharma plc - Class A (NASDAQ:RPRX)

About Royalty Pharma plc - Class A

News

Quick info

Royalty Pharma plc - Class A income statements (2023) (USD)

Royalty Pharma plc - Class A income statements (2022) (USD)

Royalty Pharma plc - Class A income statements (2021) (USD)

Royalty Pharma plc - Class A balance sheet (2023) (USD)

Royalty Pharma plc - Class A balance sheet (2022) (USD)

Royalty Pharma plc - Class A balance sheet (2021) (USD)

Royalty Pharma plc - Class A cash flow (2023) (USD)

Royalty Pharma plc - Class A cash flow (2022) (USD)

Royalty Pharma plc - Class A cash flow (2021) (USD)

Royalty Pharma plc - Class A dividends (USD)

Total Valuation

Important Dates

Share Statistics

Valuation Ratios

Stock Price Statistics

Income Statement

About

Key Executives